Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab in resectable oral cavity squamous cell carcinoma
2017-000577-36Phase 2Active
- Sponsor
- UZ Leuven
- Start
- Jul 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in Oral Mucosal Carcinoma, sponsored by UZ Leuven. Started Jul 2018; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2017-000577-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000577-36.